Bioengineered Chewing Gum Cut HPV Levels by 93% in Lab Tests — But It’s Not a Treatment Yet
Researchers at the University of Pennsylvania School of Dental Medicine have found that extracts from a bioengineered chewing gum sharply reduced levels of HPV and two bacteria linked to head and neck cancer in laboratory testing on patient samples — a finding that’s drawing attention as a potential future therapy, even though it’s not something anyone can use to prevent or treat cancer today.
What the Study Actually Found
The research, led by Henry Daniell, the W.D. Miller Professor and vice-chair of the Department of Basic and Translational Sciences at Penn Dental Medicine, examined oral samples from patients with head and neck squamous cell carcinoma (HNSCC). Researchers treated those samples in the laboratory with extracts from the bioengineered gum and measured what happened to three microbes associated with the disease: human papillomavirus (HPV), and two bacteria, Porphyromonas gingivalis and Fusobacterium nucleatum.
The results were striking. According to Penn Today, bean gum extracts reduced HPV levels by 93% in saliva samples and by 80% in oral rinse samples. When researchers added a second ingredient — an antimicrobial peptide called protegrin — a single dose reduced levels of the two cancer-linked bacteria to almost zero, without affecting the beneficial bacteria normally present in the mouth. The findings were published in the journal Scientific Reports.
An Important Caveat: This Was a Lab Test, Not a Clinical Trial
It’s essential to be clear about what this study did and didn’t test. According to Medical Daily’s careful framing of the research, the work is preclinical — no person actually chewed the gum as a treatment in this study. Instead, researchers took oral samples from patients and treated those samples with gum extracts in a laboratory setting, then measured the effect on the microbes present. That design cannot establish whether chewing the gum would actually prevent or treat cancer in a real person, and the researchers themselves do not claim that it does.
This distinction matters because it separates genuine scientific promise from something people could act on today. Medical Daily was explicit on this point: nothing commercially available contains the specific antiviral protein, called FRIL, at the concentrations tested, or the protegrin-1 peptide at all, and any product marketed on the basis of this research would not be the substance actually studied.
How the Gum Is Made
The gum builds on earlier research using a substance derived from lablab beans, also called hyacinth beans or bean gum. According to reporting from Pittsburgh public radio station WESA, researchers grow the beans in Daniell’s Philadelphia laboratory, then turn them into a powder containing a naturally occurring antiviral protein called FRIL. That powder is sent to a third-party manufacturer, which produces it into a chewing gum. Researchers then add protegrin, the antimicrobial peptide capable of killing harmful bacteria, to create the final formulation.
Daniell described the mechanism to WESA using a simple analogy: the gum acts like a “fly trap,” binding to and neutralizing viruses and harmful bacteria in the mouth as a person chews. “It’s not going to kill one virus,” Daniell said. “It’s going to clean out pretty much every virus in the oral cavity.”
Why Researchers Are Focused on HPV Specifically
The rationale for targeting HPV centers on a specific and largely unaddressed medical gap. According to Medical Daily, persistent oral infection with high-risk HPV is associated with increased risk of cancers of the oropharynx — the middle part of the throat, including the tonsils and base of the tongue — and there is currently no treatment aimed specifically at clearing an established oral HPV infection.
Daniell put the broader trend in context in comments to Dental Tribune International: “The global increase in oropharyngeal cancer has been linked to HPV-16, a high-risk type of HPV.” The Oral Health Group separately quoted Daniell noting that lip and oral cavity cancer was the seventh leading cancer type by incidence and mortality worldwide among adolescents, young adults, and middle-aged adults in 2022, underscoring the scale of the problem this line of research is aimed at addressing.
How This Compares to Existing Cancer Treatment
One notable advantage researchers highlighted is the gum’s selectivity. According to Penn Today, the bioengineered formulation reduced harmful bacteria without affecting the beneficial bacteria normally found in the mouth — a contrast with radiation therapy, which both reduces beneficial oral bacteria and increases disease-causing yeast such as Candida albicans as a side effect.
Daniell framed the broader clinical need driving this research in comments cited by the Oral Health Group, noting that most recently approved cancer drugs have not significantly improved quality-of-life or five-year survival outcomes for head and neck cancer patients — part of why his team sees value in pursuing lower-cost, more targeted approaches like this one.
What Comes Next
The researchers themselves have been clear about the path forward. Daniell said the findings “support the value of advancing these therapies to clinical trials as adjuvants with current treatments or as prophylaxis to prevent infection and transmission,” according to ScienceDaily’s coverage of the study. That means the next step would involve testing the actual gum in human clinical trials — either alongside existing cancer treatments or as a preventive measure — a process that typically takes years before any product could become available for real-world use.
What Actually Prevents HPV-Related Cancers Today
While this research develops, existing prevention tools remain the most reliable option available now. According to Medical Daily, HPV vaccination protects against the high-risk HPV types responsible for most HPV-associated cancers, including oropharyngeal cancer, and is routinely recommended starting at ages 11 to 12, with vaccination possible as early as age 9. Catch-up vaccination is recommended through age 26 for those not adequately vaccinated earlier, and adults aged 27 through 45 can discuss vaccination with a clinician based on individual circumstances. Not smoking, limiting alcohol consumption, and attending regular dental visits — where dentists and hygienists can identify oral lesions early — also reduce overall risk of head and neck cancers.
FAQ
Can this chewing gum treat or prevent cancer right now? No. This was a laboratory study on patient samples, not a clinical trial involving people actually chewing the gum. The researchers have not claimed it can prevent or treat cancer, and no commercial product containing the tested formulation currently exists.
How much did the gum reduce HPV levels in the study? Extracts from the gum reduced HPV levels by 93% in saliva samples and 80% in oral rinse samples taken from patients with head and neck squamous cell carcinoma.
What is the gum made from? It’s derived from lablab beans (also called hyacinth beans), which contain a naturally occurring antiviral protein called FRIL. Researchers also added an antimicrobial peptide called protegrin to enhance its effect against bacteria.
Does this replace HPV vaccination? No. HPV vaccination remains the primary, medically established way to prevent the high-risk HPV infections linked to most HPV-associated cancers and is recommended starting at ages 11 to 12.
What are the next steps for this research? The researchers say the findings support moving toward human clinical trials, testing the gum either as an addition to existing cancer treatments or as a preventive measure against infection and transmission.
Conclusion
This research represents a genuinely promising early step rather than a ready-to-use therapy — a distinction worth keeping in mind given how easily “93% reduction” headlines can outrun what a preclinical, sample-based study actually shows. With human clinical trials still ahead and no commercial product currently matching what was tested, the most concrete, immediately actionable tools for reducing HPV-related cancer risk remain the ones already available: vaccination, avoiding tobacco and excess alcohol, and regular dental checkups.
Sources: Penn Today, ScienceDaily, Medical Daily, WESA/NPR, Dental Tribune International, Oral Health Group (reporting dated May-August 2026, based on research published in Scientific Reports).